Credit Suisse Thinks Teva Pharma’s Stock is Going to Recover

By Carrie Williams

Credit Suisse analyst Vamil Divan maintained a Buy rating on Teva Pharma (NYSE: TEVA) on May 15 and set a price target of $39. The company’s shares opened today at $31.54, close to its 52-week low of $30.20.

According to TipRanks.com, Divan is a 3-star analyst with an average return of 3.4% and a 52.8% success rate. Divan covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.

Currently, the analyst consensus on Teva Pharma is Moderate Buy and the average price target is $38.38, representing a 21.7% upside.

In a report issued on May 11, Oppenheimer also reiterated a Buy rating on the stock with a $41 price target.

Teva Pharma’s market cap is currently $32.29B and has a P/E ratio of 214.58. The company has a book value ratio of 1.0647.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following two segments: Generic and Specialty Medicine. The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment includes several franchises, most significantly core therapeutic areas of CNS medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.